We have evaluated the potential usefulness of indium-111 labelled [DTPA-D-Phel]RC-160, derived from the octapeptide somatostatin analogue RC-160, as a radiopharmaceutical for the in vivo detection of somatostatin receptor-positive tumours. For this purpose 111In-and 11Sin-labelled [DTPA-D-Phe~]RC-160 was tested for its biological activity, and applied for somatostatin receptor scintigraphy in vivo to rats bearing the transplantable rat pancreatic tumour CA20948, which expresses somatostatin receptors. We previously described the development of the 1HIn-labelled somatostatin analogue 
Introduction
High numbers of high-affinity somatostatin receptors for both native somatostatin (for structures, see Fig. 1 ) and the synthetic octapeptide octreotide (Sandostatin), have been detected on most neuro-endocrine tumours, like endocrine pancreatic tumours and carcinoids [1] [2] [3] [4] . We, and also others, have recently described the visualization of somatostatin receptor-positive tumours in vivo after the intravenous administration of [123I-Tyr3]octreotide [5] [6] [7] [8] [9] [10] [11] [12] and [UlIn-DTPA-D-Phel]octreotide [13] [14] [15] [16] [17] [18] [19] [20] . Several reports have also been published on the in vitro binding to somatostatin receptors of another somatostatin analogue, the octapeptide RC-160 [21] [22] [23] . It has been reported that RC-160 has a higher affinity than octreotide for somatostatin receptors in human breast, ovarian, exocrine pancreatic, prostatic and colonic cancers [21] [22] [23] . A phase 1 clinical trial with RC-160 in patients with advanced exocrine pancreatic cancer suggests that RC-160 is well tolerated at doses up to 1500 ~tg/day [24] [25] . The possibility of RC-160 binding to a somatostatin receptor subtype, which does not bind octreo- tide, for example on human exocrine pancreatic adenocarcinomas [26] , offers a potential advantage of RC-160 over octreotide as radiolabelled tumour tracer. Furthermore, RC-160 and radioiodinated RC-160 may, in contrast to octreotide [27] , also pass the blood-brain barrier [28] [29] [30] . This could represent a benefit in visualizing somatostatin receptor-positive brain tumours with an intact blood-brain barrier. We recently reported [30] our results with tumour visualization with ~23I-RC-160 in tumour-bearing rats and concluded that, despite the fact that 123I-RC-160 shows high-affinity binding to various somatostatin receptor-positive tissues and tumours, no advantage over [123I-Tyr3]octreotide has been found in binding to the somatostatin receptor-positive tissues and tumours studied so far. Therefore, we compared [H~In-DTPA-D-Phel]RC-160 with [HlIn-DTPA-D-Phel]octreotide (for structure see Fig. 1 ), as radiopharmaceuticals for scintigraphy in normal rats and in rats bearing the transplantable pancreatic somatostatin receptor-positive tumour CA20948 [26, 31, 32] . [33] . Although it is not excluded that additional groups of the peptides participate in 11 ~In complexation, the labelled products are referred to as [~ ~In-DT-PA-D-Phez]RC -160 and [l~ iin_DTPA_D_Phe~ ]octreotide. The radiochemical purity of the radiolabelled somatostatin analogues was greater than 95 %. All chemicals used were of the highest purity available.
Materials and methods

Animals and tumours.
Male Lewis rats (240-260 g) were inoculated in both upper hind legs with the transplantable rat pancreatic tumour CA20948, wich has previously been shown to possess somatostatin receptors [26] . Mate Lewis rats (240-260 g) not bearing the CA20948 tumour were used as control rats. For injection and scintigraphy the rats were anaesthetized with ether.
In order to study specific binding, the rats were injected subcutaneously with 1 mg RC-160 or l mg octreotide in 1 ml 0.05 M acetic acid containing 154 mM NaC1 or solvent. Forty-five minutes later the rats were injected with either [H*In-DTPA-DPhel]RC-160 or [mIn-DTPA-D-Phea]octreotide. Specific binding was defined as the difference between the tissue uptake in tumourinoculated rats and that in similar animals treated with excess of unlabelled peptide, expressed as percentages of the injected radioactivity per gram tissue (mean _+ SD).
The tracer agents were injected into the dorsal vein of the penis. The dose was 18.5 MBq (0.5 ~g) for both analogues, measured in a dose calibrator (VDC-202, Veenstra, Joure, The Netherlands). The rats were sacrificed 2, 4, 24, 48 or 72 h after administration of the radiolabelled somatostatin analogue. The concentration of radioactivity in various tissues, urine and blood was subsequently measured. [~HIn-DTPA-D-Phe~]octreotide and [ll~in_DT_ PA-D-PheJ]RC-160 binds to SEP-PAK C~8 stationary phase and is, using the separation technique as described by Bakker [6] , only eluted with ethanol, while mIn-DTPA does not retain on SEP-PAK C~8 columns. Radioactivity in plasma and urine samples which is also eluted with ethanol from the SEP-PAK C~s column is termed peptide-bound radioactivity, but is not further characterized.
The radioactivity in blood and urine was analysed as described previously [6] .
Biological activity and radioligand binding studies. [34] . Receptor binding assays were carried out using [~2SI-Tyr3]octreotide as described previously [35] .
Binding curves and IC50 for displacement of [mSI-Tyr3]octreotide binding by unlabelled peptide were calculated from two experiments (triplicate determinations) using the computer fitting program of Graphpad (ISI software, Philadelphia, Pa., USA).
Data acquisition and analysis. All results are expressed as the mean + SD. One-way analysis of variance (ANOVA), was used for statistical analysis. For the comparison of means the NewmanKeuls or Bonfen-oni t-test was applied [36] . A P value of <0.05 was considered significant. The tissue distribution and metabolism of the '~XIn-labelled somatostatin analogues in vivo were studied by gamma camera scintigraphy (Rota-II, Siemens) [13] and measurement of rain in isolated organs was performed using an LKB-1282-Compugammasystem.
The ratio of tissue-binding values of tissue over soft tissue (thigh) and the radioactivity concentration ratio of tumour over soft tissue were calculated for each individual organ and for the tumours. No significant differences were found at equimolar concentrations significant differences between the effects of the two l~SIn-labelled and the two non-labelled somatostatin analogues (P > 0.05, Student's t-test). Trivalent indium ions, up to a concentration of 8 -10 .5 M, did not influence rat growth hormone assay (data not shown).
Results
Quality control, radiolabeIling and preparation of the radiopharmaceutical
Receptor binding studies and biological activity
Tissue distribution and specific binding
The radioactivities measured in the isolated tumour and (Table 1) . Despite the decrease in radioactivity in most somatostatin receptor-negative tissues, i.e. in the majority of tissues, total body radioactivity does not decrease between 24 and 48 h after the injection of [11tln-DTPA-DPhel]RC-160, due to an increase of radioactivity in the kidneys (Table 1) For instance about 50% of injected [1HIn-DTPA-DPhel]octreotide is excreted via the kidneys in the first 30 min after injection, as described previously by Bakker et al. [13] .
In Table 2 the specific binding at several time intervals after injection of [11qn-DTPA-D-Phel]RC-160 and [11qn-DTPA-D-Phe~]octreotide is given for the somatostatin receptor-positive tissues and tumour. There were no significant differences in binding of either peptide to these sites. Also, no specific binding of either analogue was found in the brain, suggesting that they were unable to pass the blood-brain barrier. From digital static images obtained 24, 48 and 72 h after injection of [~In-DTPA-D-Phe~]RC-160, wholebody retention was found to be approximately 50% of the injected dose after 48 h and 72 h, and this retention was predominantly accounted for by radioactivity in the kidneys (see also Table 1 ). Figure 4 presents static analog images of two rats with unilateral somatostatin receptor-positive CA20948 tumours, 24 h after the injection of [mIn-DTPA-D-Phel]RC-160. Accumulation of radioactivity in the tumour and kidneys was observed. The uptake of radioactivity by the tumour was successfully inhibited by the pretreatment of unlabelled RC-160 (Fig. 4) .
Discussion
Like octreotide, RC-160 is a somatostatin analogue with potent hormone secretion-inhibitory and antiproliferative characteristics in vivo and in vitro. However, discrepancies with octreotide have been described with regard to binding to a number of human cancers, such as breast, ovarian, exocrine pancreas, prostate, and colon carcinomas [21] [22] [23] . Because radiolabelled RC-160 could have advantages over radiolabelled octreotide for the in vivo detection of some of these somatostatin receptor-positive tumours, at first we evaluated radioiodinated RC-160 as a radiopharmaceutical. These studies revealed some major drawbacks of 123I-RC-160 as compared to [123I-Tyr3]octreotide. The main disadvantage of ~23I-RC-160 was its relatively low tumour to background ratio, implying poorer in vivo tumour detection [30] . In analogy with the development of [mIn-DTPA-D-Phel]octreotide we therefore evaluated [~In-DTPA-D-Phe~]RC -160. Since for use in animal models no somatostatin receptorpositive tumours are available displaying binding specificity for RC-160 and not for octreotide, we investigated both somatostatin analogues in the CA20948 tumour model.
The radiolabelling of [DTPA-D-Phel]RC-160 with (high-quality) ~ltIn is a simple single-step procedure with a high efficiency of labelling (> 95%) and does not require special skills or equipment. We found no significant differences in biological activity between [38] . In the perfused rat liver uptake of radioactivity from the medium was 20% of the dose in the liver during the first hour of perfusion with [111In-DTPA-D-Phel]RC-160, but 2% of the dose for [11qn-DTPA-D-Phel]octreotide. Less than 1% of the dose of both radiolabelled somatostatin analogues was excreted in the bile, where they were in the peptide-bound form.
The presence of the C-terminal amino acid tryptophan in RC-160 (see Fig. 1 We currently investigate patients with a negative [HlIn-DTPA-D-Phel]octreotide gamma camera scintigraphy who have tumours which do not bind octreotide, but belong to the group of tumours which Schally et al. suggested to have a high affinity for RC-160 [21] [22] [23] . The therapeutic possibilities of [~3q-Tyr3]octreotide are low [7] , since the residence time of 131I in the tumour is short. This is because radioiodinated [Tyr3]octreotide is rapidly metabolized with release of 131I in the circulation, as has been demonstrated previously in rats [6, 30] and patients [7] .
Since the residence time in/on the tumour cells of somatostatin analogues with a DTPA group appears prolonged, it seems worthwhile to investigate whether DT-PA peptides labelled with L31I or other 13-emitting radionuclides would be suitable for radiotherapy. Therefore, 
